Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Expenses (2016 - 2026)

Rocket Pharmaceuticals' Accumulated Expenses history spans 11 years, with the latest figure at $12.3 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 2.93% to $12.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.3 million, a 2.93% increase, with the full-year FY2025 number at $12.3 million, up 2.93% from a year prior.
  • Accumulated Expenses hit $12.3 million in Q4 2025 for Rocket Pharmaceuticals, up from $11.4 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for RCKT hit a ceiling of $12.3 million in Q4 2025 and a floor of $123000.0 in Q2 2021.
  • Historically, Accumulated Expenses has averaged $5.9 million across 5 years, with a median of $6.0 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: tumbled 96.89% in 2021 and later skyrocketed 2344.72% in 2022.
  • Tracing RCKT's Accumulated Expenses over 5 years: stood at $725000.0 in 2021, then surged by 188.97% to $2.1 million in 2022, then soared by 373.99% to $9.9 million in 2023, then grew by 20.28% to $11.9 million in 2024, then rose by 2.93% to $12.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for RCKT at $12.3 million in Q4 2025, $11.4 million in Q3 2025, and $8.0 million in Q2 2025.